AbbVie ROE 2010-2018 | ABBV

Current and historical return on equity (ROE) values for AbbVie (ABBV) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. AbbVie ROE for the three months ending September 30, 2018 was 2006.63%.
AbbVie ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $7.57B $-2.92B 1285.47%
2018-06-30 $6.45B $-3.38B 215.65%
2018-03-31 $6.38B $3.55B 119.57%
2017-12-31 $5.31B $5.10B 93.18%
2017-09-30 $6.65B $6.69B 119.09%
2017-06-30 $6.62B $6.01B 119.66%
2017-03-31 $6.31B $5.00B 116.08%
2016-12-31 $5.95B $4.64B 111.33%
2016-09-30 $6.08B $6.47B 117.49%
2016-06-30 $5.72B $5.64B 119.85%
2016-03-31 $5.48B $4.64B 115.56%
2015-12-31 $5.14B $3.95B 131.15%
2015-09-30 $2.82B $4.86B 83.55%
2015-06-30 $2.08B $5.50B 62.83%
2015-03-31 $1.82B $1.38B 55.95%
2014-12-31 $1.77B $1.74B 43.53%
2014-09-30 $3.71B $4.65B 77.93%
2014-06-30 $4.17B $5.22B 92.75%
2014-03-31 $4.14B $4.70B 101.45%
2013-12-31 $4.13B $4.49B 113.22%
2013-09-30 $4.54B $3.58B 134.97%
2013-06-30 $5.16B $3.56B 80.81%
2013-03-31 $5.36B $2.96B 64.01%
2012-12-31 $5.28B $3.36B 49.54%
2012-09-30 $4.89B $15.67B 38.25%
2012-06-30 $3.32B $11.51B 37.42%
2012-03-31 $3.59B $12.05B 59.93%
2011-12-31 $3.43B $11.93B 115.09%
2011-09-30 $2.28B $0.00B 57.98%
2011-06-30 $2.26B $0.00B 57.65%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $134.597B $28.216B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $396.345B 18.58
Pfizer (PFE) United States $262.998B 14.83
Merck (MRK) United States $205.854B 17.84
Novartis AG (NVS) Switzerland $204.655B 17.49
Eli Lilly (LLY) United States $122.680B 21.57
Sanofi (SNY) France $112.713B 13.96
Novo Nordisk (NVO) Denmark $111.107B 18.04
AstraZeneca (AZN) United Kingdom $103.342B 12.83
GlaxoSmithKline (GSK) United Kingdom $101.256B 13.61
Bristol-Myers Squibb (BMY) United States $87.290B 14.38